Overall, our results suggest that multiple pathways of EV biogenesis may operate in glioma cells resulting in formation of complex EV landscapes consisting of EGFR-positive and EGFR-negative EV subsets. This heterogeneity may have important implications for EV functions and EV-based diagnostics.
Accordingly, silencing RAB4A significantly increased the fusion of multivesicular bodies with the plasma membrane followed by EV secretion, suggesting that TGF-β-induced RAB4A acts as a negative feedback regulator of EV release. Our findings reveal a novel mechanism by which RAB4A modulates TGF-β-driven EV production by cancer cells.
These findings indicate that urinary EVs provide highly pure vesicles with superior DNA quality, making them a robust and completely non-invasive source for molecular profiling. Urinary EV-DNA-based MRD assessment shows significant prognostic value and may serve as a practical tool for postoperative monitoring and risk stratification in colorectal cancer.
Integrated EV and serological profiling may enable minimally invasive differentiation between HCC and iCCA within LR-M lesions. By transforming ML-guided model discovery into a clinically interpretable paper-and-pencil additive score, we illustrate a translational pathway from computational discovery to practical application.
The BiacoreTM biosensor is able to directly detect and molecularly profile EVs in buffer and spiked in cell culture supernatant supplemented with 10% EV-depleted serum. Altogether, our findings illuminate the potential of SPR BiacoreTM technology in EV-related research as well as reveal the diagnostic potential of EV-associated CXCR4, offering valuable insights and paving the way for medical applications in diseases associated with aberrant CXCR4 expression.
These multifaceted effects collectively alleviated mHtt aggregation, as confirmed by EM48 immunostaining and Western blot analysis. Together, our findings demonstrate that iPSC-exo mitigate HD pathology by improving mitochondrial function, neuronal differentiation, and anti-apoptotic signaling, thereby reducing mHtt accumulation.
24 days ago
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CD81 (CD81 Molecule) • DLG4 (Discs Large MAGUK Scaffold Protein 4)
TNBC cell lines MDA-MB-231 and taxol-resistant MDA-MB-231TR were sensitive to growth inhibition by CBD than estrogen receptor positive (ER+) MCF-7 and its taxol-resistant derivative MCF-7TR...These findings highlight the potential of FA-ExoCBD to enhance CBD's anticancer efficacy through targeted gene modulation. Overall, FA-ExoCBD improves CBD's therapeutic profile by enhancing efficacy, tumor selectivity, improved bioavailability and anticancer efficacy.
At the mechanistic level, the RIP assay (anti-IL-4 antibody pull-down) suggests that LINC01614 may directly interact with IL-4. In summary, this study preliminarily reveals the mechanism by which LINC01614 promotes Treg differentiation and M2 polarization through the exosome pathway to regulate the immune microenvironment of gastric cancer, providing a theoretical basis for targeting LINC01614 to enhance immunotherapy.
Proof-of-concept was gained for the detection of PSMA-positive EVs in urine from prostate cancer patients and discrimination of breast cancer patients from healthy donors by quantifying EpCAM- or HER2-positive EVs in blood plasma. In conclusion, using low-volume biofluids, the one-step AF4-MALS-FLD workflow holds potential for fast and robust EV biomarker detection.
These findings demonstrate that MSC-derived exosomes can efficiently encapsulate and deliver PTX, enhancing its antitumor efficacy. This exosome-based platform offers a promising strategy to overcome pharmacological barriers and improve therapeutic outcomes in PDAC.
Also, to successfully detect markers, e.g. Hsp70 or CD44, in serum EVs we demonstrated to require more intense sample preparation in specific assays. While more patient studies are needed in the future, this pilot study paves the way for understanding the molecular differences in the DLBCL subtypes and for detecting them in the lymphoma EVs.